Butcher Arthur C, EVP & Group President of MedSurg & APAC, has demonstrated a clear bias toward selling shares in Boston Scientific Corporation (BSX) based on SEC Form 4 filings. Over 66 reported transactions, Butcher has sold shares totaling approximately $11.95 million, significantly outweighing purchases of $1.99 million. Notably, all recent activity has been focused on selling, with no buys recorded in the latest filings. On December 1, 2025, Butcher sold shares worth $1.76 million, followed by another sale on August 1, 2025, valued at $1.81 million. Earlier transactions in February 2025 also reflect this trend, with sales totaling $270,156.06 across multiple filings.
The pattern extends into 2026, with Butcher continuing to divest shares. On February 19, 2026, shares worth $519,031.76 were sold, preceded by smaller transactions on February 16 ($91,843.17) and February 14 ($114,710.55). The largest sale in this period occurred on February 13, 2026, with shares valued at $1.88 million. These filings indicate a consistent and substantial reduction in Butcher’s holdings in BSX, with no recent acquisitions to offset the divestments. The data underscores a clear and ongoing trend of selling activity, reflecting a strategic reduction in equity exposure within Boston Scientific Corporation.
AI-assisted summary